Metabolic health isn’t static. Glucose levels change throughout the day.
Unlike traditional studies that rely solely on fasting labs, this trial incorporated three full days of continuous glucose monitoring at baseline and post-intervention — capturing real-world glucose exposure, peaks, and variability.
This allowed researchers to measure:
- 24-hour total glucose exposure (AUC)
- Mean and maximum daily glucose
- Glycemic variability (MAGE, MoDD)
- Basal hyperglycemia (overnight burden)
What We Found
After 4 weeks of supplementation, participants receiving NCT/NFT showed statistically significant improvements compared to placebo in:
- Total 24-hour glucose AUC
- Mean and maximum 24-hour glucose
- Glycemic variability
- Basal hyperglycemia
These findings demonstrate reduced overall glucose burden and improved glucose stability — both critical to long-term metabolic health.
Together with our first publication, this creates a comprehensive evidence package spanning both static biomarkers and real-world glucose dynamics.
The Power of an Integrated AI Platform
NCT and NFT were identified using Brightseed’s AI platform, which maps plant compounds to human biology. Our technology predicted their activity on HNF4α, a master regulator of glucose metabolism — and we translated that prediction into precision-fermented ingredients and clinically validated outcomes.
From computational insight → mechanism → clinical proof. In record time.
This second publication reinforces what’s possible when AI, biology, and rigorous clinical science are integrated into one platform.
Nature holds millions of undiscovered bioactives. We’re building the engine to unlock them — and bring clinically validated solutions to market faster than ever before.
Read the full study in Bioactive Compounds in Health and Disease (2026).
